The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]
Mary Hamby, PhD
Advertisement
Articles by Mary Hamby, PhD
The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhDPublished: April 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
2
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
3
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
4
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD
5
